Back to Search
Start Over
Osilodrostat: First Approval.
- Source :
-
Drugs [Drugs] 2020 Apr; Vol. 80 (5), pp. 495-500. - Publication Year :
- 2020
-
Abstract
- Osilodrostat (Isturisa <superscript>®</superscript> ) is an orally available small molecule 11β-hydroxylase inhibitor that is being developed by Novartis for the treatment of Cushing's disease. Based on results from a pivotal phase III trial, osilodrostat was approved in the EU for use in the treatment of endogenous Cushing's syndrome in adults and is under regulatory review in the USA for the treatment of Cushing's disease. This article summarises the milestones in the development of osilodrostat leading to this first approval.
- Subjects :
- Administration, Oral
Cushing Syndrome metabolism
Enzyme Inhibitors administration & dosage
Enzyme Inhibitors chemistry
Humans
Imidazoles administration & dosage
Imidazoles chemistry
Molecular Conformation
Pyridines administration & dosage
Pyridines chemistry
Steroid 11-beta-Hydroxylase metabolism
Cushing Syndrome drug therapy
Drug Approval
Enzyme Inhibitors pharmacology
Imidazoles pharmacology
Pyridines pharmacology
Steroid 11-beta-Hydroxylase antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1179-1950
- Volume :
- 80
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Drugs
- Publication Type :
- Academic Journal
- Accession number :
- 32141023
- Full Text :
- https://doi.org/10.1007/s40265-020-01277-0